Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19.

Objective: To test the hypothesis that coronavirus disease 2019 (COVID-19) has an impact on the CNS by measuring plasma biomarkers of CNS injury.

Methods: We recruited 47 patients with mild (n = 20), moderate (n = 9), or severe (n = 18) COVID-19 and measured 2 plasma biomarkers of CNS injury by single molecule array, neurofilament light chain protein (NfL; a marker of intra-axonal neuronal injury) and glial fibrillary acidic protein (GFAp; a marker of astrocytic activation/injury), in samples collected at presentation and again in a subset after a mean of 11.4 days. Cross-sectional results were compared with results from 33 age-matched controls derived from an independent cohort.

Results: The patients with severe COVID-19 had higher plasma concentrations of GFAp ( = 0.001) and NfL ( < 0.001) than controls, while GFAp was also increased in patients with moderate disease ( = 0.03). In patients with severe disease, an early peak in plasma GFAp decreased on follow-up ( < 0.01), while NfL showed a sustained increase from first to last follow-up ( < 0.01), perhaps reflecting a sequence of early astrocytic response and more delayed axonal injury.

Conclusion: We show neurochemical evidence of neuronal injury and glial activation in patients with moderate and severe COVID-19. Further studies are needed to clarify the frequency and nature of COVID-19-related CNS damage and its relation to both clinically defined CNS events such as hypoxic and ischemic events and mechanisms more closely linked to systemic severe acute respiratory syndrome coronavirus 2 infection and consequent immune activation, as well as to evaluate the clinical utility of monitoring plasma NfL and GFAp in the management of this group of patients.